Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Review

COVID-19 and Parkinson’s disease: Defects in neurogenesis as the potential cause of olfactory system impairments and anosmia

Harini Sri Rethinavel a,1, Sowbarnika Ravichandran a,b,1, Risna Kanjirassery Radhakrishnan a,1, Mahesh Kandasamy a,b,c,e

a Laboratory of Stem Cells and Neuroregeneration, Department of Animal Science, School of Life Sciences, Bharathidasan University, Tiruchirappalli, 620024, Tamil Nadu, India
b School of Life Sciences, Bharathidasan University, Tiruchirappalli, 620024, Tamil Nadu, India
c Faculty Recharge Programme, University Grants Commission (UGC-FRP), New Delhi, 110002, India

doi: 10.1016/j.jchemneu.2021.101965

A R T I C L E   I N F O

ABSTRACT

Anosmia, a neuropathogenic condition of loss of smell, has been recognized as a key pathogenic hallmark of the current pandemic SARS-CoV-2 infection responsible for COVID-19. While the anosmia resulting from olfactory bulb (OB) pathology is the prominent clinical characteristic of Parkinson’s disease (PD), SARS-CoV-2 infection has been predicted as a potential risk factor for developing Parkinsonism-related symptoms in a significant portion of COVID-19 patients and survivors. SARS-CoV-2 infection appears to alter the dopamine system and induce the loss of dopaminergic neurons that have been known to be the cause of PD. However, the underlying biological basis of anosmia and the potential link between COVID-19 and PD remains obscure. Ample experimental studies in rodents suggest that the occurrence of neural stem cell (NSC) mediated neurogenesis in the olfactory epithelium (OE) and OB is important for olfaction. Though the occurrence of neurogenesis in the human forebrain has been a subject of debate, considerable experimental evidence strongly supports the incidence of neurogenesis in the human OB in adulthood. To note, various viral infections and neuropathogenic conditions including PD with olfactory dysfunctions have been characterized by impaired neurogenesis in OB and OE. Therefore, this article describes and examines the recent reports on SARS-CoV-2 mediated OB dysfunctions and defects in the dopaminergic system responsible for PD. Further, the article emphasizes that COVID-19 and PD associated anosmia could result from the regenerative failure in the replenishment of the dopaminergic neurons in OB and olfactory sensory neurons in OE.

1. Introduction

The coronavirus disease (COVID-19) pandemic continues due to the spread of new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection worldwide (Kandasamy, 2020; Korber et al., 2020; Lai et al., 2020; Krishna Murthy et al., 2021; Selvaraj et al., 2021; Zheng, 2020). The typical symptoms of COVID-19 include anosmia and ageusia along with fever, dry cough and shortness of breath (Ali and Alharbi, 2020; Huang et al., 2020; Kandasamy, 2020a; Meng et al., 2020). The angiotensin-converting enzyme 2 (ACE2) and

https://doi.org/10.1016/j.jchemneu.2021.101965
Received 25 February 2021; Received in revised form 2 May 2021; Accepted 6 May 2021
Available online 11 May 2021
0891-0618/© 2021 Elsevier B.V. All rights reserved.
transmembrane serine protease 2 (TMPRSS2) expressing ciliated cells of the nasal mucosa are the primary targets of initial SARS-CoV-2 infection (Beghi et al., 2020; Sungnak et al., 2020). A higher level of viral load is found in the nasal cavity of both symptomatic and asymptomatic SARS-CoV-2 infected individuals (Gengler et al., 2020; Meng et al., 2020; Ra et al., 2021). SARS-CoV-2 spreads from nasal epithelium to different brain regions through the neural pathway of the olfactory bulb (OB) and induces cytokine storm responsible for neuroinflammation, thereby leading to various neurological deficits (DosSantos et al., 2020; Zhang et al., 2020). Anosmia, a clinical state of loss of smell, has been ascertained as a key symptom of COVID-19 regardless of the diagnostic criteria, sex and age (Aziz et al., 2021; Jain et al., 2020; Spinato et al., 2020). Anosmia can either occur as the only symptom in COVID-19 subjects or take place along with other clinical signs of COVID-19 (Lechien et al., 2020; Meng et al., 2020). While the duration of anosmia may be shorter in most COVID-19 cases, it may also be irreversible in subjects with severe OB dysfunction (Gori et al., 2020; Vavougios, 2020). At present, the underlying pathogenic basis for anosmia in patients with COVID-19 remains obscure. Several magnetic resonance imaging (MRI) and computerized tomography (CT) based brain imaging reports, and neuro clinical correlates have clearly indicated the dysfunction or atrophy of OB in subjects with COVID-19 (Chiu et al., 2020; Galougaib et al., 2020; Kandemirli et al., 2021). Defect in the dopamine system, OB pathology and loss of smell are the prominent clinical characteristics of Parkinson’s disease (PD) (Balestino and Schapira, 2020; Barresi et al., 2012; Haehner et al., 2011; Kouli et al., 2018). However, the underlying biological basis of anosmia and the potential link between COVID-19 and PD remains obscure.

Ample experimental studies in rodents suggest that the occurrence of neural stem cell (NSC) mediated neurogenesis in the olfactory epithelium (OE) and OB is important for the sense of smell (Brann and Firestein, 2011; Lledo and Valley, 2016), whereas impairment of olfactory neurogenesis due to various pathogenic stimuli including neuroinflammation and oxidative stress is associated with loss of smell (Boesveldt et al., 2017; Lazarini et al., 2014). Notably, the regulation of neurogenesis in OB is negatively altered during viral infections and various neuropathogenic conditions including PD (Kandasamy et al., 2015; Lazarini et al., 2014; Loseva et al., 2009; May et al., 2012). Though the occurrence of neurogenesis in the human OB is a controversial subject (Bergmann et al., 2012), there exists considerable experimental evidence that strongly supports the incidence of ongoing neurogenesis in the human OB during adulthood (Durante et al., 2020; Lazarini et al., 2014; Lledo and Valley, 2016; Pignatelli and Belluzzi, 2010; Winner et al., 2006). Therefore, this article attempts to survey the recent reports on SARS-CoV-2 mediated dysfunction in OB and defects in the dopaminergic system responsible for PD. Further, this article postulates a hypothesis that anosmia resulting from pathogenic events of COVID-19 and PD could be linked to dysregulation of adult neurogenesis in OB and OE.

2. Frequency of anosmia and olfactory dysfunction in COVID-19

The SARS-CoV-2 infection has been known to cause olfactory dysfunction in the majority of COVID-19 cases (Meng et al., 2020; Sedaghat et al., 2020; Sungnak et al., 2020). Several recent reports indicate that the neuroinvasion of SARS-CoV-2 initially induces neuroinflammation-mediated damage to the olfactory receptor neurons (ORNs) of the nasal neuroepithelium and spread to other brain regions via OB (Gori et al., 2020; Mahalaximi et al., 2021). Hyposmia or anosmia has been reported to be highly prevalent among COVID-19 patients (Meng et al., 2020; Sedaghat et al., 2020; Speth et al., 2020). A retrospective study by Lechien JR et al. reported the occurrence of 85.6 % and 88 % of olfactory and gustatory dysfunctions respectively in patients with mild to moderate symptoms of COVID-19 (Lechien et al., 2020). A smartphone-app-based COVID-19 like symptom tracker study by Menni C et al. revealed a strong association between the loss of smell in 64.76 % of patients who confirmed positive for SARS-CoV-2 infection by real-time reverse transcription-polymerase chain reaction (RT-PCR) (Menni et al., 2020). A clinical report from China indicated 5.1 % of hospitalized COVID-19 patients experiencing loss of smell (Mao et al., 2020). Klopfenstein T et al. reported that 47 % of COVID-19 patients in Europe exhibited anosmia along with dysgeusia (Klopfenstein et al., 2020). Von Bartheld CS et al. reported higher incidences of olfactory impairments and taste disorders in COVID-19 cases in the Western population than in COVID-19 patients in East Asia, and the difference appears to be independent of age and disease severity (von Bartheld et al., 2020). Quantitative meta assessments of the olfactory defects upon SARS-CoV-2 infection reported some degree of loss of smell in nearly all COVID-19 patients worldwide (Moine et al., 2020; Mullol et al., 2020). There exist many reports that describe olfactory dysfunction varies from person to person irrespective of age. A Spanish multicenter cross-sectional study by Rojas-Lechuga MJ et al. indicated that 70.1 % of COVID-19 subjects confirmed by RT-PCR with a mean age of 46.5 ranging from 21 years to 89 years reported the occurrence of smell loss (Rojas-Lechuga et al., 2021). Gori A et al. indicated that COVID-19 causes severe complications in patients with advanced chronological age due to age-related defects of olfactory neuroepithelium and deterioration of OB homeostasis (Gori et al., 2020). An Italian multicenter study by Vaira LA et al. reported that 51.5 % of COVID-19 patients showed olfactory disorders regardless of the difference in gender and age (Vaira et al., 2020). In the meantime, Giacomelli A et al. reported 5.1 % of COVID-19 cases at the mean age group of 60 with OD in the Italian population (Giacomelli et al., 2020). A UK based cohort study by Tomlins, J. et al. reported 4% of SARS-CoV-2 positive subjects with anosmia in the median age group of 75 (Tomlins et al., 2020). A study by Bénézit F et al. indicated 20 % of hyposmia among COVID-19 patients in France who were tested positive for the presence of SARS-CoV-2 by RT-PCR (Bénézit et al., 2020). Luers JC et al. reported that 73.6 % of COVID-19 patients (mean age 38) confirmed by RT-PCR showed olfactory dysfunction (Luers et al., 2020). In a pilot multicenter case-control study from Spain, Beltrán-Corbellini. A et al. reported anosmia in 45.2 % of COVID-19 patients (mean age 52.6) confirmed by RT-PCR (Beltrán-Corbellini et al., 2020). Notably, a case-control study by Mangal V et al. observed a significant prevalence of olfactory dysfunction in asymptomatic cases with SARS-CoV-2 infection (Mangal et al., 2021). An olfactory-action meter-based study by Bhattacharjee AS et al. revealed a significant reduction in the smell detection abilities of asymptomatic COVID-19 subjects compared to normal healthy individuals (Bhattacharjee et al., 2020).

Given the comorbid pathological nature of SARS-CoV-2 infection, neuropathogenesis seen in COVID-19 appears to be overlapped with the clinical characteristic of the sporadic form of various neurodegenerative disorders (Ferini-Strambi and Salsone, 2020; Kandasamy, 2020; Marshall, 2020; Rebholz et al., 2020). However, studies on abnormal cellular and molecular bases for the neurological deficits in COVID-19 are at the early stage. Anosmia resulting from OB pathology is the prominent clinical characteristic of many neurodegenerative disorders including Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS) (Hawkes, 2003; Rebholz et al., 2020). The degree of olfactory dysfunction in many neurodegenerative diseases varies and occurs along with other symptoms in the late stage of the disease (Doty, 2017; Rebholz et al., 2020). Unlike other neurological diseases, anosmia resulting from the pathogenesis of AD has been associated with an early and likely clinical feature of PD (Doty, 2017, 2012). The SARS-CoV-2 infection has been predicted as a potential risk factor for developing Parkinsonism-related symptoms in a significant portion of COVID-19 patients and survivors (Brundin et al., 2020; Sulzer et al., 2020). SARS-CoV-2 infection appears to induce defects in the dopamine system, loss of dopaminergic neurons, and accelerates synucleinopathies in the brain which have been considered as the underlying causes of PD (Brundin et al., 2020; Li et al., 2020a,b; Merelio et al., 2021; Sulzer et al., 2020).
loss of dopaminergic neurons in the substantia nigra leading to failure in
functionality (Brundin et al., 2020; Sulzer et al., 2020). Thus, a reciprocal link between COVID-19 and PD has become a topic of scientific focus.

3. Possible relationship between COVID-19 and Parkinson’s disease

While age and age-related diseases are the major risk factors of COVID-19 infection, recent reports indicated the possibilities for the occurrence of PD upon SARS-CoV-2 infection (Sulzer et al., 2020). PD is one of the common late-onset neurodegenerative disorders mainly characterized by movement disorders including bradykinesia, tremor, imbalance and rigidity with postural instability (DeMaagd and Philip, 2015; Greenland and Barker, 2018; Koul et al., 2018; Williams and Litvan, 2013). The movement disorders in PD arises mainly due to the loss of dopaminergic neurons in the substantia nigra leading to failure in the nigrostriatal pathway of the brain (Alexander, 2004; Sonne et al., 2020). The dysfunction of the dopaminergic system and degeneration of dopaminergic neurons in the OB contribute to olfactory defects in PD (Alexander, 2004; Pañé et al., 2020). Besides, PD has been characterized by the presence of Lewy bodies and α-Synucleinopathy due to a dysfunctional proteostasis network in the brain (Beyer et al., 2009; Lehtonen et al., 2019). Several lines of evidence states that the impairment of the sense of smell in PD could also be due to Lewy bodies and aggregation of α-Synuclein mediated failure of the dopaminergic system in OB (Han et al., 2020; Rey et al., 2018; Sengoku et al., 2008). Many recent studies indicate that PD results from unknown complex interactions between the genetic and environmental factors, while mutations in some genes including alpha-Synuclein, Parkin, and Leucine-rich repeat kinase 2 (LRKK2) leads to genetic forms of PD (Nuytemans et al., 2010). There exists a considerable number of experimental proofs that viral infections can trigger the accumulation of Lewy bodies and α-Synuclein in the brain (Takahashi and Yamada, 1999; Tulisiak et al., 2019).

Previous case reports suggest that transient secondary parkinsonism can result from several viral infections including human immunodeficiency virus (HIV), Japanese encephalitis (JE) and coxsackie viruses (Jang et al., 2009a). Limphaibool N et al. reported that herpes simplex 1, Epstein-Barr, hepatitis C, and influenza A virus can also increase the chance of developing PD in the long run (Limphaibool et al., 2019). With reference to the alteration of the dopaminergic system upon viral infections, an earlier study by Jang H et al. showed that intranasally infected newborn mouse brains of subjects with COVID-19 could interfere with the clearance of α-Synuclein, thereby resulting in its abnormal aggregation (Pavel et al., 2020). Considering the fact, it can be expected that the impairment in neuronal replacement of dopaminergic neurons in OB may be responsible for the loss of smell in PD and COVID-19. Therefore, the dysregulation of the synthesis of dopamine, degeneration of dopaminergic neurons and impaired neuroregenerative potential of NSCs in the olfactory system resulting from SARS-CoV-2 infection may collectively contribute to the risk of developing the sporadic form of PD in COVID-19 patients and survivors.

4. The olfactory system and its cellular components and a revisit on neurogenesis in the olfactory bulb in adult humans

The olfactory system plays an important role in communicating the chemosensory input to the brain (Pinto, 2011; Sharma et al., 2019). In vertebrates, the olfactory system is comprised of the main olfactory system (MOS) and the accessory olfactory system (AOS) (Taniguchi et al., 2011). The MOS contains OE in the nasal cavity responsible for recognizing volatile compounds, while the AOS has the vomeronasal organ through which the non-volatile pheromones are identified (Mucignat-Caretta, 2010; Suárez et al., 2012; Vargas-Barroso et al., 2017). OE is composed of olfactory sensory neurons (OSNs), multipotent basal neuronal stem cells such as globose basal cells (GBCs) and horizontal basal cells (HBCs) (Cartier et al., 2004). In addition, OE contains supporting cell populations like microvillar cells, sustentacular cells, and Bowman’s gland lining cells (Choi and Goldstein, 2018; Purves et al., 2001; Schwob et al., 2017). The GBCs are mitotically active cells that give rise to sustentacular cells and sensory neurons in OE (Cartier et al., 2004; Goldstein and Schwob, 1996; Leung et al., 2007). While HBCs generally remain quiescent in the physiological state, they get activated upon injury and microbial infection (Cartier et al., 2004; Iwai et al., 2008; Joiner et al., 2015). In the nasal cavity, the olfactory receptor (OR) genes are expressed mainly in the sensory neurons of OE (Dang et al., 2018; Mombaerts, 2004; Nilimura and Nei, 2006). ORs belong to G Protein-Coupled Receptor (GPCR) superfamily and are classified into two different groups, namely class I and class II, based on the phylogenetic difference in mammals (Filescher et al., 2009; Spehr and Munger, 2009). While class I receptors mediate the signaling of water-soluble odorants, class II receptors are responsible for the perception of aerial odorants (Mezler et al., 2001; Spehr and Munger, 2009). In mammals, the majority of ORs are classified as class II receptors, and class I receptors are expressed to a lesser extent (Bozza et al., 2009; Ferrer et al., 2016). The odorant molecule dissolves in the mucus layer of OE and activates the ORNs (Izquierdo-Dominguez et al., 2020; Nagashima and Touhara, 2010). The bipolar ORNs extend axons through the cribriform plate and make the synaptic connection with the dendrites of neurons in the glomeruli of OB (Beites et al., 2009; Choi and Goldstein, 2018). In addition to OE, the other two regions of MOS
include the Grüneberg ganglion (GG) and the septal organ (SO) which send projections to OB (Suárez et al., 2012). In turn, OB transfers the information to other brain regions through the olfactory cortex (Gireneo et al., 1997; Semendeferi et al., 1997). OB consists of multiple layers that include the olfactory nerve layer (ONL), glomerular layer (GML), external plexiform layer (EPL), mitral cell layer (MCL), internal plexiform layer (IPL) and granule cell layer (GCL) (Nagayama et al., 2014). The synaptic organization in different layers of OB is evident in rodent brains, whereas in humans, the circumferential organization of layers and medial-lateral symmetry are not well defined (Marash et al., 2008). There are two types of neurons that project via the olfactory tract to higher areas of cortical centers, namely mitral cells located in MCL and tufted cells in EPL (Harvey and Heinbockel, 2018; Nagayama et al., 2014). The axons of ORNs synapse with the dendrites of mitral and tufted cells in OB (Kim et al., 2020; Nezlin et al., 2003; Vassar et al., 1994). The mitral cells project their axons from OB to other regions of the brain (Igarashi et al., 2012; Nagayama et al., 2010). The OB also contains dopaminergic neurons in the GML and periglomerular area which plays a prominent role in the detection, discrimination as well as modulation of odour (Paë et al., 2020; Pignatelli and Belluzzi, 2017). Dopaminergic neurons in OB appear to modulate the activity of olfactory sensory fibers, mitral cells and tufted cells together with granule neurons of GCL (Berkowicz and Trombley, 2000; Cave and Baker, 2009; Pignatelli and Belluzzi, 2017). Notably, the granule neurons of GCL and dopaminergic neurons of GML in OB are constantly generated through the cellular regenerative process known as adult neurogenesis (Kandasamy et al., 2015; Lazarini et al., 2014).

In most vertebrates, neurogenesis in the olfactory system is crucial for daily life activities including food-seeking, pathfinding, social interactions and sexual behaviours (Feierstein, 2012). In OE, locally residing NSCs and progenitor cells such as HBCs and GBCs represent the cellular regenerative resource for the continual generation of new ORNs throughout adulthood (Bram and Firestein, 2014). Besides, rodent studies have established that NSCs in the subventricular zone (SVZ) generate immature neurons called neuroblasts which migrate through the rostral migratory stream (RMS) to OB where they differentiate and functionally integrate as gamma aminobutyric acid (GABA)ergic and dopaminergic interneurons (Kandasamy et al., 2015; Ming and Song, 2011; Winner et al., 2006). The occurrence of adult neurogenesis in OB responsible for olfaction has also been reported in many other mammalian species including primates (Kornack and Rakic, 2001). Unlike in rodents, an extra migratory stream containing immature neurons towards the ventromedial prefrontal cortex has been reported in forebrains of human infants (Sanai et al., 2011). Considering the fact, local progenitor cells residing in the human olfactory system in OB has been speculated to be responsible for adult neurogenesis (Pagano et al., 2009). However, the occurrence of adult neurogenesis in the forebrain of humans has been a controversial subject (Berger et al., 2020; Sanai et al., 2011). The studies support evidence that neurogenesis in the SVZ takes place in the adult human brain but it is less active compared to the brains of adult rodents (Parolisi et al., 2018). The rate of turnover of new neurons in the human brain appears to be relatively slow (Bergmann et al., 2012; Spalding et al., 2013). A previous carbon dating analysis of the neuronal DNA indicated that the occurrence of neurogenesis is highly limited in the adult human OB (Ernst and Friean, 2015; McGann, 2017). However, subsequent studies revealed strong evidence for the existence of ongoing neurogenesis in the human olfactory system in adulthood (Bram and Firestein, 2014; Curtis et al., 2012; Liu and Martin, 2003; Whitman and Greer, 2009). An immunofluorescence labelling study by Bédard and Parent, reported the expression of well-known markers of neurogenesis such as Doublecortin (DCX), NeuroD, polysialylated-neural cell adhesion molecule (PSA-NCAM) and TuJ1 in OB of the human brains (Bédard and Parent, 2004). Using a transcriptome analysis, Lötch et al. validated the existence of neurogenic markers in OB of the adult human brain (Lötch et al., 2014). Besides, it has been testified that transcriptional profiles of the basal progenitor populations of HBCs and GBCs present in the adult human OB are similar to that of rodent brains (Schwob et al., 2017). A recent single-cell RNA sequencing and immunohistochemical analysis by Durante et al. demonstrated the presence of NSCs and immature neurons in the human OB (Durante et al., 2020). Even though the morphology and cellular marker expression patterns of human and rodent OB may differ to some extent, both human OB and OE harbour NSCs, and immature and mature newborn neurons (Lledo and Valley, 2016; Song et al., 2016; Whitman and Greer, 2009). Moreover, neurospheres derived from human olfactory mucosa biopsies appeared to have self-renewing capacity and differentiated into neurons and glial cells (Murrell et al., 2005). Taken together, the presence of NSCs and the occurrence of neurogenesis in the olfactory system of the human brain is increasingly evident.

The ongoing adult neurogenesis in the forebrain has been linked to the maintenance and rewiring of the neural circuit in the olfactory system (Pignatelli and Belluzzi, 2010). Notably, adult neurogenesis in OB is important for odour-based learning, odour discrimination, and mating behaviours (Lledo and Valley, 2016; Pignatelli and Belluzzi, 2010). Moreover, a number of neurodegenerative diseases including PD have been characterized by impaired neurogenesis in OB which is accountable for deficits in olfactory neuroplasticity, leading to anosmia (Höglinger et al., 2004; Marxreiter et al., 2013; Winner et al., 2006; Winner and Winkler, 2015). Besides, many viruses including rhinovirus, Epstein bar virus, and coronaviruses are known to induce dysfunction of OB due to inflammation (Bonzano et al., 2020; Lechien et al., 2020; Suzuki et al., 2007; van Riel et al., 2015). While neuroinflammation has been known to suppress the proliferation of NSCs and adult neurogenesis (Fan and Pang, 2017; Kandasamy et al., 2020, 2015, 2011, 2010), the possibilities of SARS-CoV-2 infection-mediated defect in neurogenesis responsible for anosmia in the olfactory system may not be excluded.

5. Impaired neurogenesis in the olfactory system as a potential cause of anosmia in COVID-19 and PD

In general, upper respiratory tract infection has been known to be associated with OB dysfunction (Welge-Lüssen and Wolfsberger, 2006). However, the occurrence of anosmia resulting from OB pathology has been reported in the majority of COVID-19 cases regardless of the onset of respiratory dysfunctions (Whitcroft and Hummel, 2020). Thus, the World Health Organization (WHO) has recognized anosmia as a distinct early symptom of SARS-CoV-2 infection. Similarly, anosmia has been well recognized as a pre-clinical symptom of PD (Fullard et al., 2017). To note, the sensory neurons that express the odorant receptors responsible for the sense of smell are continuously replenished throughout life unlike the other nerve cells in mammalian brains (Bram and Firestein, 2014). In the olfactory system, these sensory neurons of OE project excitatory synapses with inhibitory interneurons in GCL of OB through the generation of axonal binding in GML (Imamura et al., 2020; Lledo et al., 2008). Notably, ORNs in OE are known to be positive for the markers of immature neurons such as DCX during their generation in adulthood (Saaltink et al., 2012). While the inhibitory interneurons play a major role in the synaptic input of sensory neurons (Arnson and Strowbridge, 2017; Lledo et al., 2004), adult neurogenesis contributes to the generation of GABAergic inhibitory interneurons in GCL of OB (Lledo and Valley, 2016; Pallotto and Deprez, 2014).
Moreover, the axonal processing of sensory neurons in glomeruli appears to be important for the olfactory discrimination (Malnic et al., 2010), in which, continual generation of dopaminergic neurons from NSCs and neural progenitors appears to be highly important (Kandasamy et al., 2015; Lazarini et al., 2014; Pignatelli et al., 2009) Thus, the regulation of olfactory neurogenesis provides a cellular mechanism for the sense of smell in physiological conditions (Gheusi and Lledo, 2014).

To note, reduction of dopamine in the adult brain appears to alter the number of mitotic cells in the forebrain of PD patients and the animal models of PD (Höglinger et al., 2004; Winner et al., 2006). O’Sullivan et al. reported the negative correlation between disease duration and the number of Musashi-positive NSCs of SVZ in the postmortem brain samples of non-dementia PD victims (O’Sullivan et al., 2011). Moreover, Ziaireva I et al. have also validated the reduced number of Musashi-positive NSCs and progenitor cells of SVZ in the postmortem brain with Lewy body pathology (Ziaireva et al., 2007). Moreover, many experimental models of PD have been characterized by impaired neurogenesis in OB (May et al., 2012; Winner and Winkler, 2015).

Notably, neuroinflammation appears to impair adult neurogenesis in various neurodegenerative conditions including PD (Kandasamy et al., 2020, 2011; Taupin, 2008). While reduction of dopamine synthesis has been known to cease the neurogenic capacity of the adult brain, blockade of neuroinflammation appears to enhance adult neurogenesis, thereby compensating the replenishment of the dopaminergic neurons in OB and restores olfactory sensory processing in PD (Lazarini et al., 2014).

Previously, the extent of epithelial destruction and load of SARS-CoV-2 in OB has been correlated to the varying severity of olfactory dysfunction responsible for anosmia (Akerlund et al., 1995; Imam et al., 2020; Yamagishi et al., 1988). Recently, it has been speculated that the loss of smell noticed in COVID-19 arises because of defects in the supporting cells of CE and vascular pericytes of OB, that could induce a change in the function of ORNs (Butowt and von Bartheld, 2020; Solomon, 2021; Vaira et al., 2020). A case study testified that obstruction in the olfactory cleft caused by inflammation may be a possible reason for anosmia in COVID-19 (Eliazer et al., 2020), while RNA sequencing and immunostaining studies revealed that ORNs and OE are positive for ACE2 and TMRPRSS2 (Bilinska et al., 2020; Brann et al., 2020). However, Naenie A et al. did not find any significant mucosal changes or olfactory cleft abnormality in the CT imaging in COVID-19 patients with anosmia and thereby highlighted further experiments are required to elucidate the aetiology of olfactory loss in COVID-19 (Naenie et al., 2020). Gane SB et al. hypothesized that anosmia in COVID-19 patients could occur due to the destruction of the ORNs in OE (Gane et al., 2020). The whole RNA sequencing data of olfactory mucosa in humans showed that the expression of SARS-CoV-2 entry related genes are prominent in most neuronal cells of the olfactory system including NSCs and progenitors (Brann et al., 2020). Considering the aforementioned facts, the regenerative aspect of the human olfactory system responsible for the production of new neurons that involves the sense of smell needs to be revisited in COVID-19 conditions. Notably, many neurological deficits noticed in COVID-19 have been related to neuroinflammation due to the prominent cytokine storm (Kandasamy, 2021). Thus, neuroinflammation has been recognized as a key determinant for the abnormalities noticed in the dopaminergic system in substantia nigra and OB responsible for anosmia in PD (Höglinger et al., 2004; Taupin, 2008). The proliferative and differentiation potentials of NSCs are known to be drastically impaired by neuroinflammation in PD. Therefore, it can be hypothesized that the pathogenesis of COVID-19 associated neuroinflammation could be an underlying basis for the defect in the dopaminergic system leading to the development of sporadic PD. Eventually, the pathogenic events of PD and COVID-19 might be in part overlapped by impaired NSC-mediated neurogenesis in OB and OE leading to anosmia.

6. Conclusion

The human OE is highly sensitive to environmental changes and susceptible to the chemosensory deprivation and inflammation. OB plays an intermediate role between OE and higher brain areas to process the odour information. The regulation of NSC-mediated neurogenesis in OB and OE is important for olfaction. While the regulation of neurogenesis in OB and OE is negatively influenced by neuroinflammation, olfactory impairments resulting from neuroinflammation represent a pathogenic interlink between COVID-19 and PD. Considering the fact, SARS-CoV-2 infection in the nasal route may be associated with a reduction in the NSC population of GBCs and HBCs which are involved in renewing the ORNs in OE. Besides, the SARS-CoV-2-mediated neuroinflammation in OB would also be associated with the impairment of neurogenesis at the level of defects in proliferation and dopaminergic differentiation of NSCs in the proximity of GML similar to the pathogenesis seen in PD. Thus, failure in the replenishment of degenerating ORNs in OE and dopaminergic neurons in OB in subjects with COVID-19 and PD might be the underlying basis of anosmia. To defend and overcome this obstacle, the delivery of programmed drugs and therapeutic measures against dopamine alterations needs to be considered to manage COVID-19. Also, further experiments are indispensable to analyze neurogenesis and the overlapping mechanisms with other neurological diseases in the brains of COVID-19 patients.

Author contributions

MK conceived the present idea, hypothesis and generated the illustration. HSR, SR and RKR further developed the hypothesis and performed the literature search and made the initial draft. HSR, SR, RKR and MK contributed to the revision of article, made critical comments and suggestions. All authors discussed the content and contributed to the final manuscript.

Declaration of Competing Interest

The authors report no declarations of interest.

Acknowledgment

M.K. has been supported by the Faculty Recharge Programme, University Grants Commission (UGC-FRP), New Delhi, India. M.K. received a research grant (SERB-EEQ/2016/000639) and an Early Career Research Award (SERB-ECR/2016/000741) from the Science and Engineering Research Board (SERB), government of India. The authors acknowledge, RUSA (Rashtriya Uchchatar Shiksha Abhiyan) 2, Biological Sciences, Bharathidasan University for the financial support, UGC-SAP, DST-FIST for the infrastructure of the Department of Animal Science, Bharathidasan University. R.K.R. was supported as JRF from the project grant-ECR/2016/000741, SERB.

References

Akerlund, A., Bende, M., Murphy, C., 1995. Olfactory threshold and nasal mucosal changes in experimentally induced common cold. Acta Otolaryngol. 115, 88–92. https://doi.org/10.3109/00016489509133353.

Alexander, G.E., 2004. Biology of Parkinson's disease: pathogenesis and pathophysiology of a multisystem neurodegenerative disorder. Dialogues Clin. Neurosci. 6, 259–260.

Ali, I., Albari, O.M.L., 2020. COVID-19 disease, management, treatment, and social impact. Sci. Total Environ. 728, 138861 https://doi.org/10.1016/j.scitotenv.2020.138861.

Aronson, H.A., Strawbridge, B.W., 2017. Spatial structure of synchronized inhibition in the olfactory bulb. J. Neurosci. 37, 10468–10480. https://doi.org/10.1523/JNEUROSCI.0044-17.2017.

Aziz, M., Goyal, H., Haghibin, H., Lee-Smith, W.M., Gajendran, M., Perisetti, A., 2021. The association of “Loss of smell” to COVID-19: a systematic review and meta-analysis. Am. J. Med. Sci. 361, 216–225. https://doi.org/10.1016/j.amjms.2020.09.017.

Balestrino, R., Schapira, A.H.V., 2020. Parkinson disease. Eur. J. Neurol. 27, 27–42. https://doi.org/10.1111/ene.14108.

https://doi.org/10.1111/ene.14108.
Barreto, M., Cielo, R., Giaccoppo, S., Celi, D., Barresi, M., Ciurleo, R., 2020. Evaluation of olfactory dysfunction in neurodegenerative diseases. J. Neurosci. 37, 7403–7412.
Bébere, A., Parenti, A., 2004. Evidence of newly generated neurons in the human olfactory bulb. Dev. Brain Res. 151, 159–168. https://doi.org/10.1016/j.dbr.2004.03.032.
Beghi, E., Feigin, V., Van, L., Arora, R., 2015. Parkinson’s Disease and its Management. P 40, 5-32.
Dos Santos, M.F., Devolle, S., Aran, V., Capra, D., Roque, N.R., Coelho-Aguiar, J., de, M., Spolar, T.C., Udo, S., Subhajita, J.G., Pereira, C.M., D’Andrea Meira, I., Niemeyer, Soares Filho, P., Moura-Neto, V., 2020. Neuromechanisms of SARS-CoV-2: a review. Front. Neurosci. 14, 532. https://doi.org/10.3389/fnene.2020.00537.
Doty, R.L., 2012. Olfaction in Parkinson’s disease and related disorders. Neurobiol. Dis. 46, 527–552. https://doi.org/10.1016/j.nbd.2011.10.026.
Doty, R.L., 2017. Olfactory dysfunction in neurodegenerative diseases: is there a common pathological substrate? Lancet Neurol. 16, 478–488. https://doi.org/10.1016/S1474-4422(17)30123-5.
Durante, M.A., Kurtenbach, Stefan, Sargi, Z.B., Harb, J.W., Choi, R., Kurtenbach, Sarah, Goss, G.M., Matsunami, H., Goldstein, B.J., 2020. Single-cell analysis of olfactory neurogenesis and differentiation in adult humans. Nat. Neurosci. 23, 323–326. https://doi.org/10.1038/s41593-020-0587-9.
Eliezer, M., Hautefort, A., Haude, B., Herman, P., Houdart, E., Elot, C., 2020. Sudden and complete olfactory loss as a possible symptom of COVID-19. JAMA Otolaryngol. Head Neck Surg. 146, 674–675. https://doi.org/10.1001/jamaoto.2020.0832.
Ernst, A., Frisen, D., 2015. Adult neurogenesis in humans—common and unique traits in mammals. PLoS Biol. 13. https://doi.org/10.1371/journal.pbio.1002045.
Faber, I., Brandao, P.R.F., Menegatti, F., de Carvalho Birgo, D.D., Maluf, E.B., Cardoso, F., 2020. Coronavirus disease 2019 and parkinsonism: a non-post-encephalitic case. Mov. Disord. 35, 1721–1722. https://doi.org/10.1002/mds.29277.
Fan, J.W., Fang, Y., 2017. Disregulation of neurogenesis by neuroinflammation: key differences in neurodevelopmental and neurological disorders. Neural Regen. Res. 12, 366–371. https://doi.org/10.1634/nrr.2017029296.
Feuerstein, C.E., 2012. Linking adult olfactory neurogenesis to social behavior. Front. Aging Neurosci. 4, 173. https://doi.org/10.3389/fnagi.2012.00173.
Ferini-Strambi, L., Salone, M., 2020. COVID-19 and neurological disorders: are they related? Lancet Neurol. 19, 46–52. https://doi.org/10.1016/S1474-4422(20)30223-4.
Galioglu, M.K., Ghorbani, J., Bakhshayeekaram, M., Naeini, A.S., Haseli, S., 2020. Olfactory bulb magnetic resonance imaging in SARS-CoV-2-Induced anosmia: the first report. Acad. Radiol. 27, 892–893. https://doi.org/10.1016/j.acra.2020.04.002.
Gane, S.B., Kelly, C., Hopkins, C., 2020. Isolated sudden onset anosmia in COVID-19 infection. A novel syndrome? Rhinology 58, 299–301. https://doi.org/10.4193/rhinol.2019.0047.
Ganger, I., Wang, J.C., Speth, M.M., Sedaghat, A.R., 2020. Sinonasal pathophysiology of SARS-CoV-2 and COVID-19: a systematic review of the current evidence. JAMA Otolaryngol. Head Neck Surg. 146, 675–678. https://doi.org/10.1001/jamaoto.2020.0789.
Ghio, G., Lioz, P.-M., 2014. Adult neurogenesis in the olfactory system shapes odor memory and perception. Prog. Brain Res. 208, 157–175. https://doi.org/10.1016/bs.prber.2014.08.004.
Gore, A., Leone, F., Loffredo, L., Cinicola, B.L., Brindisi, G., De Castro, G., Spalice, A., Gori, A., 2020. Neurotrophic effects of a murine coronavirus. Science 369, 981–985.
Gori, A., Leone, F., Loffredo, L., Cinicola, B.L., Brindisi, G., De Castro, G., Spalice, A., Gori, A., 2020. Neurotrophic effects of a murine coronavirus. Science 369, 981–985.
Gori, A., Leone, F., Loffredo, L., Cinicola, B.L., Brindisi, G., De Castro, G., Spalice, A., Gori, A., Leone, F., Loffredo, L., Cinicola, B.L., Brindisi, G., De Castro, G., Spalice, A., 2020. Neurotrophic effects of a murine coronavirus. Science 369, 981–985.
Nataf, S., 2020. An alteration of the dopamine synthetic pathway is possibly involved in Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. Hum. Mutat. 31, 763–780. https://doi.org/10.1002/humu.21277.

O’Sullivan, S.S., Johnson, M., Williams, D.R., Revez, T., Holton, J.L., Lees, A.J., Perry, K.K., 2011. The effect of drug treatment on neurogenesis in Parkinson’s disease. Mov. Disord. 26, 693–697. https://doi.org/10.1002/mds.23302.

Pagano, S.F., Impagnatiello, F., Girelli, M., Cova, L., Grioni, E., Onofri, M., Cavallaro, M., Ettori, S., Vitello, F., Giombini, S., Solero, C.L., Parati, E.A., 2000. Isolation and characterization of neural stem cells from the adult human olfactory bulb. Stem Cells 18, 295–300. https://doi.org/10.1667/0001-1242.18.4.295.

Pallotto, M., Deprez, F., 2014. Regulation of adult neurogenesis by GABergic transmission: signaling beyond GABAergic receptors. Front. Cell. Neurosci. 8. https://doi.org/10.3389/fncel.2014.00166.

Parolis, R., Cozzi, B., Bonfanti, L., 2018. Humans and dolphins: decline and fall of adult neurogenesis. Front. Neurosci. 12. https://doi.org/10.3389/fnins.2018.00497.

Pali, T., Alsfal, M., Tolve, M., Biaas, S., Rothermel, M., Wiener, R.J., Ricke, K.M., 2020. The impact of mitochondrial dysfunction on dopaminergic neurons in the olfactory bulb and odor detection. Mol. Neurobiol. 57, 3646–3657. https://doi.org/10.1007/s12035-020-01947-w.

Pavel, A., Murray, D.K., Stoessl, A.J., 2020. COVID-19 and selective vulnerability to Parkinson’s disease. Lancet Neurol. 19, 719. https://doi.org/10.1016/S1474-4422(20)30269-9.

Pignatelli, A., Belluzzi, O., 2010. Neurogenesis in the adult olfactory bulb. In: Menini, A. (Ed.), The Neurobiology of Obliteration, Frontiers in Neuroscience. CRC Press/Taylor, Francis Group, Boca Raton (FL).

Pignatelli, A., Belluzzi, O., 2017. Dopaminergic neurons in the main olfactory bulb: an overview from an electrophysiological perspective. Front. Neurosci. 11. https://doi.org/10.3389/fnins.2017.00007.

Pignatelli, A., Ackman, J.B., Matyka, J., Steves, C.J., Spector, T.D., 2020. Real-time tracking of self-reported symptoms to predict potential COVID-19. Nat. Med. 26, 1037–1040. https://doi.org/10.1038/s41591-020-02599-5.

Pinto, J.M., 2011. Obliteration. Proc. Am. Thorac. Soc. 8, 46–52. https://doi.org/10.1513/pats.201005-035RN.

Price, J.L., Stotnick, B.M., Revial, M.F., 1991. Olfactory projections to the hypothalamus. J. Comp. Neurol. 306, 467–461. https://doi.org/10.1002/cne.903060409.

Purves, D., Augustine, G.J., Fitzpatrick, D., Katz, L.C., LaMantia, A.-S., McNamara, J.O., Williams, S.M., 2001. The olfactory epithelium and olfactory receptor neuron. Neuroscience. 2nd edition.

Ra, S.H., Lim, J.S., Kim, G., Kim, M.J., Jung, J., Kim, S.H., 2021. Upper respiratory viral load in asymptomatic individuals and mildly symptomatic patients with SARS-CoV-2 infection. Thorax. 76, 61–63. https://doi.org/10.1136/thoraxjnl-2021-215042.

Rebholz, H., Braun, R.J., Ladage, D., Knoll, W., Kleber, C., Hassel, A.W., 2020. Loss of olfactory function—early indicator for Covid-19, other viral infections and neurodegenerative disorders. Front. Neurosci. 14. https://doi.org/10.3389/fnneu.2020.569333.

Rey, N.L., Wesson, D.W., Brandin, P., 2018. The olfactory bulb as the entry site for prion disease. Neurobiol. Dis. 109, 226–248. https://doi.org/10.1016/j.nbd.2016.12.013.

Rojas-Lechuga, M.J., Izquierdo-Dominguez, A., Chiesa-Estomba, C., Colín-Herreras, C., Villareal, I.M., Cuesta-Chasco, G., Bernal-Spekelesen, M., Mullol, J., 2021. Chemosensory dysfunction in COVID-19. Otolaryngology 287, 695–702. https://doi.org/10.1002/otl.2020.06666-3.

Saaltink, D.-J., Havič, B., Verissimo, C.S., Lucasen, P.J., Vresenegers, E., 2012. Doublecortin and doublecortin-like are expressed in overlapping and non-overlapping neuronal classes: implications for olfactory function. J. Neurosci. 32, 950. https://doi.org/10.1523/JNEUROSCI.0363-011.2011.

Sanai, N., Nguyen, T., Ihrie, R.A., Mirzadeh, Z., Tsai, H.-H., Wong, M., Gupta, N., Perry, C., 2021. Acute hypokinetic-rigid syndrome following SARS-CoV-2 infection. Neurology 95, e2109. https://doi.org/10.1212/WNL.0000000000002476.

Schwob, J.E., Jiang, W., Holfbrook, E.H., Lin, B., Herrick, D.B., Peterson, J.N., Coleman, J.H., 2017. Stem and progenitor cells of the mammalian olfactory epithelium: taking poietic license. J. Comp. Neurol. 525, 1034–1054. https://doi.org/10.1002/cne.24105.

Sedaghat, A.R., Gengler, I., Speeth, M.M., 2020. Olfactory dysfunction: a highly prevalent symptom of COVID-19 with public health significance. Otolaryngol. Head Neck Surg. 163, 12–15. https://doi.org/10.1177/0194599619882540.

Selvaraj, R., Ravichandran, S., Krishnan, S., Radhakrishnan, R.K., Manicamp, N., Kandasamy, M., 2021. Testicular atrophy and hypothalamic pathology in COVID-19: possibility of the incidence of male infertility and HPG Axis abnormalities. Reprod. Biol. Endocrinol. 19, 38. https://doi.org/10.1186/s12952-021-00441-3.

Semendereci, K., Damasio, H., Frank, R., van Hoesen, G.W., 1997. The evolution of the frontal lobes: a volumetric analysis based on three-dimensional reconstructions of magnetic resonance scans of human and ape brains. J. Hum. Evol. 32, 375–388. https://doi.org/10.1006/jhev.1996.0099.

Sengoku, R., Saito, Y., Ibaruma, M., Hatsuha, S., Sakiyama, Y., Kanemaru, K., Anai, T., Sawabe, M., Tanaka, N., Mochizuki, H., Inoue, M., Kurayama, S., 2008. Incidence assessment of Levy body related alpha-synucleinopathy in aging human olfactory bulb. J. Neuropathol. Exp. Neurol. 67, 1072–1083. https://doi.org/10.1097/NEN.0b013e318188a412.

Sharma, A., Kumar, R., Aier, I., Semwal, R., Tyagi, P., Varadwaj, P., 2019. Sense of smell: spatial functional, molecular, genetic and clinical aspects and challenges in human olfactory research. Curr. Neuropharmacol. 17, 891–911. https://doi.org/10.2174/15701591X16666120095626.
